Estrogen receptor-α36 is involved in pterostilbene-induced apoptosis and anti-proliferation in in vitro and in vivo breast cancer

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Pan, Chi ^a   Hu, Yiwang ^b   Li, Jun ^a   Wang, Zhaoyi ^c   Huang, Jianjin ^a   Zhang, Suzhan ^a   Ding, Ling ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CASPASE 3; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA36; ESTROGEN RECEPTOR ALPHA66; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PTEROSTILBENE; STILBENE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVATION; ER ALPHA36 GENE; ER ALPHA66 GENE; FEMALE; GENE EXPRESSION; GENE SILENCING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MCF 7 CELL LINE; MOUSE; MOUSE MODEL; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BREAST TUMOR; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; HUMAN; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION; GENE SILENCING; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; STILBENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84940233359     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104459     Document Type: Article

References (40)

1. Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, et al. (2006) Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 56: 168-183. (Pubitemid 43847927)
2. Fisher B, Redmond C, Fisher ER, Caplan R (1988) Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 6: 1076-1087.
3. Kinne DW, Butler JA, Kimmel M, Flehinger BJ, Menendez-Botet C, et al. (1987) Estrogen receptor protein of breast cancer in patients with positive nodes. High recurrence rates in the postmenopausal estrogen receptor-negative group. Arch Surg 122: 1303-1306. (Pubitemid 18021287)
4. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, et al. (2009) Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 7: 122-192.
5. Ali S, Coombes RC (2002) Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2: 101-112. (Pubitemid 37328797)
6. Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, et al. (2003) Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22: 7316-7339. (Pubitemid 37492898)
7. Roupe KA, Remsberg CM, Yanez JA, Davies NM (2006) Pharmacometrics of stilbenes: seguing towards the clinic. Curr Clin Pharmacol 1: 81-101.
8. Rimando AM, Kalt W, Magee JB, Dewey J, Ballington JR (2004) Resveratrol, pterostilbene, and piceatannol in vaccinium berries. J Agric Food Chem 52: 4713-4719.
9. Brisdelli F, D'Andrea G, Bozzi A (2009) Resveratrol: a natural polyphenol with multiple chemopreventive properties. Curr Drug Metab 10: 530-546.
10. Langcake P, Pryce RJ (1977) A new class of phytoalexins from grapevines. Experientia 33: 151-152.
11. Lin HS, Yue BD, Ho PC (2009) Determination of pterostilbene in rat plasma by a simple HPLC-UV method and its application in pre-clinical pharmacokinetic study. Biomed Chromatogr 23: 1308-1315.
12. Chakraborty A, Gupta N, Ghosh K, Roy P (2010) In vitro evaluation of the cytotoxic, anti-proliferative and anti-oxidant properties of pterostilbene isolated from Pterocarpus marsupium. Toxicol In Vitro 24: 1215-1228.
13. Moon D, McCormack D, McDonald D, McFadden D (2013) Pterostilbene induces mitochondrially derived apoptosis in breast cancer cells in vitro. J Surg Res 180: 208-215.
14. Alosi JA, McDonald DE, Schneider JS, Privette AR, McFadden DW (2010) Pterostilbene inhibits breast cancer in vitro through mitochondrial depolarization and induction of caspase-dependent apoptosis. J Surg Res 161: 195-201.
15. Mena S, Rodriguez ML, Ponsoda X, Estrela JM, Jaattela M, et al. (2012) Pterostilbene-induced tumor cytotoxicity: a lysosomal membrane permeabilization-dependent mechanism. PLoS One 7: e44524.
16. Pan MH, Lin YT, Lin CL, Wei CS, Ho CT, et al. (2011) Suppression of Heregulin-beta1/HER2-Modulated Invasive and Aggressive Phenotype of Breast Carcinoma by Pterostilbene via Inhibition of Matrix Metalloproteinase-9, p38 Kinase Cascade and Akt Activation. Evid Based Complement Alternat Med 2011: 562187.
17. Chen RJ, Tsai SJ, Ho CT, Pan MH, Ho YS, et al. (2012) Chemopreventive effects of pterostilbene on urethane-induced lung carcinogenesis in mice via the inhibition of EGFR-mediated pathways and the induction of apoptosis and autophagy. J Agric Food Chem 60: 11533-11541.
18. McCormack D, McFadden D (2012) Pterostilbene and cancer: current review. J Surg Res 173: e53-61.
19. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, et al. (2006) A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci U S A 103: 9063-9068. (Pubitemid 43902533)
20. Lee LM, Cao J, Deng H, Chen P, Gatalica Z, et al. (2008) ER-alpha36, a novel variant of ER-alpha, is expressed in ER-positive and -negative human breast carcinomas. Anticancer Res 28: 479-483.
21. Shi L, Dong B, Li Z, Lu Y, Ouyang T, et al. (2009) Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer. J Clin Oncol 27: 3423-3429.
22. Zou Y, Ding L, Coleman M, Wang Z (2009) Estrogen receptor-alpha (ER-alpha) suppresses expression of its variant ER-alpha 36. FEBS Lett 583: 1368-1374.
23. Lin SL, Yan LY, Liang XW, Wang ZB, Wang ZY, et al. (2009) A novel variant of ER-alpha, ER-alpha36 mediates testosterone-stimulated ERK and Akt activation in endometrial cancer Hec1A cells. Reprod Biol Endocrinol 7: 102.
24. Zhang J, Li G, Li Z, Yu X, Zheng Y, et al. (2012) Estrogen-independent effects of ER-alpha36 in ER-negative breast cancer. Steroids 77: 666-673.
25. Zhang XT, Kang LG, Ding L, Vranic S, Gatalica Z, et al. (2011) A positive feedback loop of ER-alpha36/EGFR promotes malignant growth of ER-negative breast cancer cells. Oncogene 30: 770-780.
26. Kang L, Wang ZY (2010) Breast cancer cell growth inhibition by phenethyl isothiocyanate is associated with down-regulation of oestrogen receptor-alpha36. J Cell Mol Med 14: 1485-1493.
27. Narayanan NK, Nargi D, Randolph C, Narayanan BA (2009) Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int J Cancer 125: 1-8.
28. Lin S-L, Yan L-Y, Zhang X-T, Yuan J, Li M, et al. (2010) ER-α36, a variant of ER-α, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways. PLoS One 5: e9013.
29. Ohshiro K, Schwartz AM, Levine PH, Kumar R (2012) Alternate estrogen receptors promote invasion of inflammatory breast cancer cells via non-genomic signaling. PLoS One 7: e30725.
30. DeSantis C, Ma J, Bryan L, Jemal A (2014) Breast cancer statistics, 2013. CA Cancer J Clin 64: 52-62.
31. (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717.
32. Pelekanou V, Notas G, Kampa M, Tsentelierou E, Radojicic J, et al. (2012) ERalpha36, a new variant of the ERalpha is expressed in triple negative breast carcinomas and has a specific transcriptomic signature in breast cancer cell lines. Steroids 77: 928-934.
33. Li G, Zhang J, Jin K, He K, Zheng Y, et al. (2013) Estrogen receptor-alpha36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells. Mol Oncol 7: 611-624.
34. Dufourny B, Alblas J, van Teeffelen HA, van Schaik FM, van der Burg B, et al. (1997) Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. J Biol Chem 272: 31163-31171. (Pubitemid 27527567)
35. Jordan NJ, Gee JM, Barrow D, Wakeling AE, Nicholson RI (2004) Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. Breast Cancer Res Treat 87: 167-180. (Pubitemid 39237793)
36. Pan MH, Chiou YS, Chen WJ, Wang JM, Badmaev V, et al. (2009) Pterostilbene inhibited tumor invasion via suppressing multiple signal transduction pathways in human hepatocellular carcinoma cells. Carcinogenesis 30: 1234-1242.
37. Wang Y, Ding L, Wang X, Zhang J, Han W, et al. (2012) Pterostilbene simultaneously induces apoptosis, cell cycle arrest and cyto-protective autophagy in breast cancer cells. Am J Transl Res 4: 44-51.
38. Chen RJ, Ho CT, Wang YJ (2010) Pterostilbene induces autophagy and apoptosis in sensitive and chemoresistant human bladder cancer cells. Mol Nutr Food Res 54: 1819-1832.
39. Kang L, Zhang X, Xie Y, Tu Y, Wang D, et al. (2010) Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling. Mol Endocrinol 24: 709-721.
40. Tu BB, Lin SL, Yan LY, Wang ZY, Sun QY, et al. (2011) ER-alpha36, a novel variant of estrogen receptor alpha, is involved in EGFR-related carcinogenesis in endometrial cancer. Am J Obstet Gynecol 205: 227 e221-226.